Quest PharmaTech Inc. (Quest) is a publicly traded (TSX Venture), Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy or photodynamic therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone.
The Company's lead product candidate, Oregovomab, an immunotherapeutic product for the treatment of ovarian cancer is currently undergoing a multi-center Phase IIb clinical trial in Italy. Enrollment in this clinical trial has been completed. This is the first of three carefully planned proof-of-concept clinical trials to establish the superiority of combinatorial immunotherapy either with front-line chemotherapy consisting of carboplatin/paclitaxel in ovarian cancer, gemcitabine in pancreatic cancer, or with the addition of an immunoadjuvant. The Company hopes that successful results from these studies will lead to the design of a definitive product registration study.
Jul 27, 2015
Quest PharmaTech Closes $1,000,000 Private Placement
Jan 13, 2015
Quest PharmaTech Announces Funding Support from National
Research Council's Industrial Research Assistance Program for IgE
Antibody Cancer Immunotherapy Development (AllergoOncology)
Nov 10, 2014
Quest PharmaTech Announces Results from its 2014 AGM
Oct 22, 2014
Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin; Dr. Jacqueline Shan, Creator of COLD FX;, to Assist
Oct 2, 2014
Quest PharmaTech Signs License Agreement with Bioceltran Co., Ltd. for Photodynamic Therapy Technology
Sep 16, 2014
Quest PharmaTech Provides Financial Update
Jun 9, 2014
Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer
Jan 29, 2014
Quest PharmaTech Announces Third Combinatorial Immunotherapy Clinical Trial for Oregovomab with a TLR3 agonist, Hiltonol®
To be announced.